ArticleScientific reports2025
A comprehensive study on drug-related Raynaud's phenomenon based on the FDA adverse event reporting system.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.Headache · 2026Pooled it
- Pharmacovigilance signals for congenital heart disease related to drug exposure: A disproportionality analysis based on the FAERS database.American heart journal plus : cardiology research and practice · 2026Article
- Article
- Drug-induced Raynaud phenomenon following initiation of metoprolol succinate.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- New-Onset Raynaud Phenomenon during Ropeginterferon Alfa-2b Therapy for Polycythemia Vera: A Case Report and Review of the Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Raynaud's phenomenon (RP) is often an overlooked adverse event, mainly secondary RP, where drug induction or exacerbation is a controllable and preventable factor. This study aimed to systematically evaluate the association between drugs and RP using the FDA adverse event reporting system (FAERS) database. Utilizing disproportionality analysis, we quantified the risk of RP-associated drugs based on large-scale FAERS case data. Drugs were categorized by ATC classification, and descriptive analyses were conducted to assess population characteristics and reporting patterns. Secondary analyses and Weibull shape parameter testing were performed to verify the reliability of the results and the temporal patterns of adverse event onset. A total of 562 drugs and 4303 cases were linked to RP. Significant signals were identified across 8 ATC categories, predominantly nervous system agents (21 drugs, n = 632), cardiovascular drugs (20 drugs, n = 403), and immunomodulators (14 drugs, n = 185). Pharmacologically, CGRP inhibitors, triptans, non-selective β-blockers, interferons, and antineoplastic/immunomodulatory agents demonstrated high mechanistic relevance to RP. Indications such as rheumatoid arthritis (256 cases, 5.95%), narcolepsy (149 cases, 3.46%), and attention-deficit hyperactivity disorder (117 cases, 2.72%) were frequently associated with RP. Cases were concentrated in individuals aged 25-59, with a female predominance (ratio 3.13:1). This study systematically reports drug-RP associations. Clinicians should consider RP risk when prescribing CGRP inhibitors, triptans, non-selective β-blockers, interferons, or antineoplastic/immunomodulatory agents. Middle-aged and elderly females, particularly those with rheumatoid arthritis, warrant heightened vigilance for drug-induced RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.